268 related articles for article (PubMed ID: 29950894)
1. Complexes formed by mutant p53 and their roles in breast cancer.
Bellazzo A; Sicari D; Valentino E; Del Sal G; Collavin L
Breast Cancer (Dove Med Press); 2018; 10():101-112. PubMed ID: 29950894
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 in Cancer Progression and Targeted Therapies.
Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
Front Oncol; 2020; 10():595187. PubMed ID: 33240819
[No Abstract] [Full Text] [Related]
3. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
Pfister NT; Prives C
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27836911
[TBL] [Abstract][Full Text] [Related]
5. The rebel angel: mutant p53 as the driving oncogene in breast cancer.
Walerych D; Napoli M; Collavin L; Del Sal G
Carcinogenesis; 2012 Nov; 33(11):2007-17. PubMed ID: 22822097
[TBL] [Abstract][Full Text] [Related]
6. Wild-type and mutant p53 in cancer-related ferroptosis. A matter of stress management?
Corazzari M; Collavin L
Front Genet; 2023; 14():1148192. PubMed ID: 37021009
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
8. [Advances on mutant p53 research].
Li DH; Zhang LQ; He FC
Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
[TBL] [Abstract][Full Text] [Related]
9. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
10. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
Eriksson M; Ambroise G; Ouchida AT; Lima Queiroz A; Smith D; Gimenez-Cassina A; Iwanicki MP; Muller PA; Norberg E; Vakifahmetoglu-Norberg H
Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993478
[No Abstract] [Full Text] [Related]
11. microRNAs: short non-coding bullets of gain of function mutant p53 proteins.
Donzelli S; Strano S; Blandino G
Oncoscience; 2014; 1(6):427-33. PubMed ID: 25594041
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
Dando I; Cordani M; Donadelli M
IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
[TBL] [Abstract][Full Text] [Related]
13. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
[TBL] [Abstract][Full Text] [Related]
14. Targeting Oncogenic Mutant p53 for Cancer Therapy.
Parrales A; Iwakuma T
Front Oncol; 2015; 5():288. PubMed ID: 26732534
[TBL] [Abstract][Full Text] [Related]
15. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
16. Disarming mutant p53 oncogenic function.
Girardini JE; Marotta C; Del Sal G
Pharmacol Res; 2014 Jan; 79():75-87. PubMed ID: 24246451
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological targeting of mutant p53.
Kogan S; Carpizo D
Transl Cancer Res; 2016 Dec; 5(6):698-706. PubMed ID: 30956950
[TBL] [Abstract][Full Text] [Related]
18. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
[TBL] [Abstract][Full Text] [Related]
19. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
Stein Y; Rotter V; Aloni-Grinstein R
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.
Roemer K
Biol Chem; 1999; 380(7-8):879-87. PubMed ID: 10494837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
